Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 18 results.
User Information
Export Records
  1. 1.   The SRC family kinase inhibitor NXP900 demonstrates potent anti-tumor activity in squamous cell carcinomas
  2. Dash,Sweta; Hanson, Sabrina; King, Ben; Nyswaner, Katherine; Foss, Kelcie; Tesi,Noelle; Harvey, Mungo J B; Navarro-Marchal, Saúl A; Woods, Allison; Poradosu, Enrique; Unciti-Broceta, Asier; Carragher, Neil O; Brognard,John
  3. The Journal of Biological Chemistry. 2024, Jul 30; 107615.
  1. 2.   Integration of Computational Docking into Anti-Cancer Drug Response Prediction Models
  2. Narykov, Oleksandr; Zhu, Yitan; Brettin, Thomas; Evrard,Yvonne; Partin, Alexander; Shukla, Maulik; Xia, Fangfang; Clyde, Austin; Vasanthakumari, Priyanka; Doroshow, James H; Stevens, Rick L
  3. Cancers. 2023, Dec 21; 16(1):
  1. 3.   Synthesis and anti-breast cancer activity of novel indibulin related diarylpyrrole derivatives
  2. Saeedian Moghadam, Ebrahim; Hamel,Ernest; Shahsavari, Zahra; Amini, Mohsen
  3. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2019, Jun; 27(1): 179-189.
  1. 4.   Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides
  2. Jun, Jung Ho; Kumar, Vineet; Dexheimer, Thomas S; Wedlich, Iwona; Nicklaus, Marc; Pommier, Yves; Malhotra, Sanjay V
  3. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2018, Jan 01; 111: 337-348.
  1. 5.   Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents
  2. Devkota, L.; Lin, C. M.; Strecker, T. E.; Wang, Y.; Tidmore, J. K.; Chen, Z.; Guddneppanavar, R.; Jelinek, C. J.; Lopez, R.; Liu, L.; Hamel, E.; Mason, R. P.; Chaplin, D. J.; Trawick, M. L.; Pinney, K. G.
  3. Bioorganic & Medicinal Chemistry. 2016, 1-Mar; 24(5): 938-56.
  1. 6.   Use of Drosophila deoxynucleoside kinase to study mechanism of toxicity and mutagenicity of deoxycytidine analogs in Escherichia coli
  2. Betham, B.; Shalhout, S.; Marquez, V. E.; Bhagwat, A. S.
  3. DNA Repair. 2010, Feb; 9(2): 153-160.
  1. 7.   A profile of the in vitro anti-tumor activity of imidazolium-based ionic liquids
  2. Malhotra, S. V.; Kumar, V.
  3. Bioorganic & Medicinal Chemistry Letters. 2010, Jan; 20(2): 581-585.
  1. 8.   Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79
  2. Kosakowska-Cholody, T.; Cholody, W. M.; Hariprakasha, H. K.; Monks, A.; Kar, S.; Wang, M. F.; Michejda, C. J.; Carr, B. I.
  3. Cancer Chemotherapy and Pharmacology. 2009 63(5): 769-778.
  1. 9.   Study on the potential anti-cancer activity of phosphonium and ammonium-based ionic liquids
  2. Kumar, V.; Malhotra, S. V.
  3. Bioorganic & Medicinal Chemistry Letters. 2009 19(16): 4643-4646.
  1. 10.   Marine pharmacology in 2003-2004: Anti-tumour and cytotoxic compounds
  2. Mayer, A. M. S.; Gustafson, K. R.
  3. European Journal of Cancer. 2006, Sep; 42(14): 2241-2270.
  1. 11.   Lessons learned fighting HIV can be applied to anti-cancer drug design
  2. Gustchina, A.; Jaskolski, M.; Wlodawer, A.
  3. Cell Cycle. 2006, MAR 1; 5(5): 463-464.
  1. 12.   Inhibition of transcription factor NF-kappa B signaling proteins IKK beta and p65 through specific cysteine residues by epoxyquinone A monomer: Correlation with its anti-cancer cell growth activity
  2. Liang, M. C.; Bardhan, S.; Pace, E. A.; Rosman, D.; Beutler, J. A.; Porco, J. A.; Gilmore, T. D.
  3. Biochemical Pharmacology. 2006, FEB 28; 71(5): 634-645.
  1. 13.   Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKC delta-dependent increase in p27(Kip1) and decrease in retinoblastoma protein (pRb) phosphorylation
  2. Vucenik, I.; Ramakrishna, G.; Tantivejkul, K.; Anderson, L. M.; Ramljak, D.
  3. Breast Cancer Research and Treatment. 2005, MAY; 91(1): 35-45.
  1. 14.   The hollow fibre model in cancer drug screening: the NCI experience
  2. Decker, S.; Hollingshead, M.; Bonomi, C. A.; Carter, J. P.; Sausville, E. A.
  3. European Journal of Cancer. 2004 40(6): 821-826.
  1. 15.   Peptides and peptidomimeties as anti-cancer therapeutics - Preface
  2. Tarasova, N. I.
  3. Current Pharmaceutical Design. 2004 10(19): i-iii.
  1. 16.   Getting back on track, or what to do when apoptosis is de-railed - Recoupling oncogenes to the apoptotic machinery
  2. Fearnhead, H. O.
  3. Cancer Biology & Therapy. 2004 3(1): 21-28.
  1. 17.   Small molecule toxins targeting tumor receptors
  2. Dyba, M.; Tarasova, N. I.; Michejda, C. J.
  3. Current Pharmaceutical Design. 2004 10(19): 2311-2334.
  1. 18.   Antifungal and cancer cell growth inhibitory activities of 1-(3 ',4 ',5 '-trimethoxyphenyl)-2-vitro-ethylene
  2. Pettit, R. K.; Hamel, E.; Verdier-Pinard, P.; Roberson, R. W.; Hazen, K. C.; Pettit, G. R.; Crews, L. C.
  3. Mycoses. 2002 45(3-4): 65-74.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel